School of Medicine

Wayne State University School of Medicine

Profile View

Ghulam Saydain, MD, FCCP
Associate Professor, Clinical Educator
Director, Pulmonary Hypertension Program
Vice President, Quality, Detroit Receiving Hospital
Full Time

Harper University Hospital
3990 John R, 3-Hudson
Detroit MI 48201

313-966 0320
Clinical Interests

 Pulmonary Hypertension, Critical Care, Adult Respiratory Distress Syndrome, Sepsis, Pulmonary  involvement in systemic diseases

Education

1984   Govt. Medical College, Srinagar
Kashmir, India
M.B.B.S. (Bachelor of Medicine & Bachelor of Surgery)

Post Graduate Training

7/1/99 to 6/30/00
Fellow, Critical Care Medicine
Mayo Graduate School of Medicine,
Mayo Clinic, Rochester, MN

7/1//97 to 6/30/99
Fellow, Pulmonary Disease
Nassau University Medical Center, NY

7/1/95 to 6/30/97
Resident, Internal Medicine
SUNY (East Meadow) Program, at
Nassau University Medical Center, NY

2/1/85 to 5/30/88
Trainee Resident for Sheri Kashmir Institute of Medical Postgraduate Course (MD) Sciences,
Srinagar, Kashmir, India in
Internal Medicine

1/20/83 to 1/19/85
Internship SMHS Hospital,
Srinagar, Kashmir,
Internal Medicine India

Faculty Appointments

05/2005- Present 
Assistant Professor of Internal Medicine
Wayne State University MI
 
07/2001-04/2005
Clinical Assistant Professor of Medicine 
State University of New York at Stony Brook, NY
 

Research Interests

Pulmonary hypertension, sepsis, prevention of health care associated infections

Research

CLINICAL TRIALS ACTIVITIES/GRANTS

2003-2005 Co-investigator World Trade Center Worker and Volunteer Medical Monitoring Program: Principal investigator Dr Benjamin Luft MD. ( I was co-investigator for the over all grant and principal investigator for this IRB approved program at our institution (Nassau University Medical Center) which is one of the sites approved for the project (2004-2005) The program is sponsored through a funded grant from CDC)

National Registries:

2007 Principal Investigator, Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL Registry), Multicenter Study. (Status : ongoing)

2007 Principal Investigator, Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH QuERI) (Status : ongoing)

Non Funded clinical Projects:

2004-2005 Principal investigator Achieving durable glucose control in the intensive care unit without hypoglycemia (multicenter clinical study)
2001-2005 Principal investigator: Respiratory diseases in workers involved in World Trade Center disaster rescue operations.
2002-2003 Principal investigator, Diffusing capacity (DLCO) in morbidly obese (MO) individuals

Commercially Sponsored Projects:

2008 ATHENA-1: A Randomized, Multicenter Study of Ambrisentan and Sildenafil Combination therapy in Subjects with Pulmonary Arterial Hypertension who have Demonstrated a Sub-Optimal Response to Sildenafil ( Approved)

2007 Principal Investigator, Effects of Combination of Bosentan and Sildenafil versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients with Pulmonary Arterial Hypertension � A Multicenter, Double-Blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study. Multicenter study sponsored by Actelion Pharmaceuticals. ( Ongoing)


2007 Principal Investigator, A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension. Multicenter Study sponsored by Eli Lilly and Co. (Status : closed)


2007 Principal Investigator, Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension. Multicenter Study sponsored by Eli Lilly and Co.


2007 Principal Investigator, Randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety, and tolerability of bosentan in patients with symptomatic pulmonary arterial hypertension associated with sickle cell disease. ASSET-1: Assessment in patients with Sickle cell disease of the Efficacy and safety of bosentan Therapy on Pulmonary arterial hypertension. Multicenter study Sponsred by Actelion Pharmaceiticals (Status : Study closed )


2007 Principal Investigator, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients with Symptomatic Pulmonary Hypertension Associated with Sickle Cell Disease. ASSET-2: Assessment in Patients with Sickle Cell Disease of the Efficacy and Safety of Bosentan Therapy on Pulmonary Hypertension. Multicenter study sponsored by Actelion Pharmaceuticals. (Status : closed)


2007 Principal Investigator, Long-Term, Open-Label, Multicenter Extension Study of Bosentan in Patients with Pulmonary Hypertension Associated with Sickle Cell Disease Completing a Double-Blind ASSET Study. ASSET-3: Assessment in Patients with Sickle Cell Disease of the Efficacy and Safety of Bosentan Therapy on Pulmonary Hypertension. Multicenter study sponsored by Actelion Pharmaceuticals. (Status : Closed)


2007 Sub-Investigator, ACCESS: A controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis. Multicenter study sponsored by Eisai. (Ongoing)


2007 Principal Investigator, A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Three-Arm Study to Evaluate the Safety and Efficacy of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) Administration in Subjects with Severe Community-Acquired Pneumonia ( closed)


2007 Principal Investigator, Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL Registry), Multicenter Study Sponsored by Actelion Pharmaceuticals. (Status : ongoing)


2007 Principal Investigator, Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH QuERI) (Status : ongoing)


2007 Sub-investigator ; A 26 week treatment multicenter, double blind, double dummy, randomized placebo-controlled seamless, parallel group study to assess the efficacy safety and tolerability of two doses of Indacterol in patients with chronic obstructive pulmonary disease, using blinded formeterol and open label tiotropium as active control. (PI: Safwan Badr, ongoing)


2007 Sub-investigator : An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the treatment of Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency� Funding Source: Altus Pharmaceuticals
PI: Dana Kissner, M.D. (Status: Open)


2007 Sub-investigator: �A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 reatment in Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency.� Funding Source: Altus Pharmaceuticals PI: Dana Kissner (Status: Open)

2007 Sub �investigator : A Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of Pulmozyme Withdrawl on Exercise Tolerance in Cystic Fibrosis Subjects with Severe Lung Disease� Funding Source:Genentech (PI: Dana Kissner Status: Open)

2003-2004 Principal investigator Role of drotrecogin Alfa (activated) Alfa in early sepsis phase III, multi-center study (Closed)

1997-1999 : Co-investigator , Safety and Efficacy of Procysteine in Patients with ARDS (Acute respiratory Distress Syndrome): Multi-center Clinical Trial Co-investigator Safety and Efficacy of Surfaxin in Patients with ARDS: Multicenter Clinical Trial.
Co-investigator: Partial Liquid Ventilation in ARDS. A Multicenter Trial.

 

Peer-Reviewed Publications

PubMed      GoogleScholar  

Original Observations

  1. Michael Balkin, Charles Mascioli�. Ghulam Saydain et al .Achieving durable glucose control in the intensive care unit without hypoglycemia : a new practical IV insulin protocol  Diabetes /Metabolism Research and Reviews 2007 Jan;23(1):49-55
 
  1. Saydain G, Beck KC, Decker P, Cowl C & Scanlon P. Clinical Significance of High Diffusing Capacity. Chest 2004 ; 125 : 446-452

3.     Saydain G, * Islam A, Afessa B, Ryu J, and Scot J & Peters S:  Outcome of Patients with Idiopathic Pulmonary Fibrosis Admitted to ICU.  Am J Resp Crit Care Med. 2002; 166 : 839-842

4.     Malik GM, Saydain G, et al:  A Logistic Model to Predict Nodal Malignancy Among Cases with Lymphadenopathy. Annals Of Saudi Medicine; 1998; 18(6): 518-52.

5.     Al-Knawy B, Morad N., Saydain G et al:  Helicobacter Pylori and Intestinal Metaplasia with its Subtypes in the Gastric Antrum in Saudi Population. Scandinavian Journal of Gastroenterology 1999; 34(6): 562-5.

6.     Mohammed A. Alhumaidi, Mostafa A Abolfotouh, Ghulam Saydain, et al: The Validity of the Reflotron as a Screening Tool for Blood Cholesterol.  The Journal of the Egyptian Public Health Association Vol.  LXXII; No 1.2 1997.

 

Reviews and Books

Review Articles:

1. Saydain G, * Raoof S, George L. Newer Therapies : Plasmapheresis, immunoglobulins and monoclonal antibodies. Critical Care Clinics 2002 ; 18: 957-975
2. Raoof S., Shah J., Saydain G et al: Role of Bronchoscopy in Human Immunodeficiency Virus-Infected Patients. Journal of Bronchology 2000; 7:326-339

Book Chapters :

  1. Ghulam Saydain & Donald A Feinfeld. Acid Base Disorders in  S. Raoof (ed): Manual of Critical Care. New York, McGraw Hill Medical 2008, pp 488-498.
Case Reports:
 

1.     Sankri-Tarbichi, AG * & Saydain G.  Reduced Lung volumes in a rare case of Cushing�s Syndrome  due to thymic carcinoid of the lung. The Journal of Respiratory Diseases, July 2008 ; 29: 281-284

2.     Saydain G, Raoof S & Khan F:  Solitary  Large Lung Mass and Amenorrhea in a Female Smoker JK-Practitioner 2002; 9(4): 244-246

3.     Saydain G*& Albright R. An Elderly Female with Increasing Thirst and Lethargy.  Mayo Clinic Proceedings 2001; 76: 1053-1056

 

 ABSTRACTS:
1. Singh J*, Subramanian M*, Levin D & Saydain G. Clinical Course of Patients With Septic Pulmonary Embolism Among Injection Drug Users With Infective Endocarditis. Oral presentation at the Annual meeting of American College of Chest Physicians Oct 2007 at Chicago IL
2. Saydain G, Singh *J and Levine, DP. Outcome of Injection Drug Users with Infective Endocarditis Admitted to ICU Poster presentation at the 9th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections Heidelberg Germany June 15 2007
3. Sankri-Tarbichi, AG* & Saydain G. Reduced Lung volumes in a rare case of Cushing�s Syndrome due to thymic carcinoid of the lung. Chest 2006; 130: 324S Oral presentation October 24 2006 Annual meeting of American College of Chest Physician .
4. G Saydain, M Rahman* , H Alnachawati* , S Mehrishi, L George, A Karnik , S Raoof. Persistent Respiratory Ailments Among Workers Responding to World Trade Center (WTC) Disaster. Presented at the American Thoracic Society international meeting at San Diego May 2006
5. Saydain G, Ali F*, Mahmood S* et al: Respiratory diseases in workers involved in World Trade Center disaster rescue operations. Oral presentation at the CHEST 2002 ( American College Of Chest Physicians at San Diego, CA in Nov. 2002), Chest 2002 ; 122: 30s (Abstract)
6. Saydain G, Beck KC et al. Clinical Significance of Isolated High Diffusing Capacity. Poster presented at ATS meeting at Atlanta, Georgia on May 21, 2002. Am J Resp Crit Care Med. 2002; 165 , A 500 ( Abstract)
7. Joseph G*, Saydain G, et al . Diffusing capacity (DLCO) in morbidly obese (MO) individuals. Poster presentation at American Thoracic Society international conference Seattle WA , on May 19, 2003
(Abstract) Am J Resp Crit Care 2003; 167 : A 421
8. Joseph G*, Awan A,�.Saydain G. et al . Elimination of tuberculosis : Is regional epidemiology important? Poster presentation at American Thoracic Society international conference Seattle WA , on May 19, 2003(Abstract) Am J Resp Crit Care 2003; 167 : A 818